Stability of human recombinant epoetin alfa in commonly used neonatal intravenous solutions

Ann Pharmacother. 1996 May;30(5):466-8. doi: 10.1177/106002809603000505.


Objective: To measure epoetin alfa concentrations after adding it to a variety of commonly used neonatal intravenous fluids to determine the stability of epoetin alfa over time.

Design: Epoetin alfa was added to the following fluids: sterile water; NaCl 0.9%; dextrose 10% in water; dextrose 10% with albumin at concentrations of 0.01%, 0.05%, and 0.1%; and total parenteral nutrition solution containing either 0.5% or 2.25% amino acids. The fluid was administered through intravenous tubing, a T-connector, and catheter, and samples were collected at 0, 2, 4, 8, and 24 hours.

Main outcome measures: Epoetin alfa concentrations were compared with the measured original preinfusion concentration and recorded as the percentage recovered.

Results: Concentrations declined significantly in all fluids containing less than 0.05% protein, but remained stable over 24 hours in fluids containing 0.05% or more protein.

Conclusions: We conclude that epoetin alfa should be mixed in intravenous fluids containing at least 0.05% protein.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Drug Stability
  • Erythropoietin / administration & dosage
  • Erythropoietin / analysis
  • Erythropoietin / chemistry*
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Infusions, Intravenous
  • Solutions / chemistry


  • Solutions
  • Erythropoietin